The telecommunications industry stands at an inflection point. What began as simple data transmission networks are rapidly evolving into intelligent infrastructure capable of processing artificial intelligence at the network edge. This transformation represents a fundamental restructuring of telecom economics, with AI-powered radio access networks (RAN) positioning data centers in billions of pockets worldwide. The global […]
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ:ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against James Hardie Industries plc. ("James Hardie" or "the Company") (NYSE:JHX) and certain of its officers. Class Definition This lawsuit seeks to recover
NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Quanex Building Products Corporation ("Quanex" or "the Company") (NYSE:NX) and certain of its officers. Class Definition This lawsuit seeks to recover damages
— Rezurock®(belumosudil tablets) now listed for public reimbursement, offering access to adult and pediatric patients 12 years and older with chronic GVHD after failure of at least two prior lines of systemic therapy — A critical step following Health Canada approval (March 2023), Canada's Drug Agency (CDA-AMC) recommendation in March 2024, and Institute of Excellence
Many users are leveraging dating apps for networking, mentorship, and even job offers ResumeBuilder.com, the premier resource for professional resume templates and career advice, has published a new survey report exploring how Americans are using dating apps for career advancement. The survey of 2,225 dating app users finds that one in three are leveraging the
— RGX-202 program forDuchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 — Pivotal trial enrollment completed in October; confirmatory trial open and enrolling — New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expected — Clemidsogene lanparvovec
Tripadvisor, Inc. (NASDAQ: TRIP) issued its third quarter 2025 earnings press release which is available now at ir.tripadvisor.com. This release is also available on the SEC website at www.sec.gov. As announced previously, the company will host a conference call this morning, Thursday, November 6, 2025, at 8:30 a.m. ET to discuss the results. The live
VENTURE Study Exploratory Analysis Shows VK2735 Improved Cardiometabolic Parameters After 13 Weeks; Reducing Prediabetes and Metabolic Syndrome Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in a
(CNSX:AGN.CN),(OTC US:AGNPF),(Other OTC:AGNPF),(CNSX:AGN),(Boerse Frankfurt – Freiverkehr:AGW0.F), VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) — Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce a non-brokered private placement for gross proceeds of $500,000 (the “Offering”) of units (the “Units”) at an issue price